A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
Pepaxto might not be a complete bust in myeloma.
Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.